VOR net incomeQ3 2026-$86.73M
VOR net income was -$86.73M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$812.68M a year earlier. For the full fiscal 2025 it was -$695.98M, compared with -$116.91M in fiscal 2024.
Vor Biopharma Inc. (VOR) financials
For the twelve months ended Sep 30, 2026, Vor Biopharma Inc. reported $1.35B of net income.
- Net income, TTM
- $1.35B
- Free cash flow, TTM
- -$119.68M
- Cash
- $78.98M
- P/E
- 0.91
- Market cap
- $1.23B
FY2020FY2025
FY2020FY2025
VOR revenue and earnings growth
VOR EPSQ3 2026-$1.45
VOR diluted EPS was -$1.45 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$70.50.
VOR free cash flowQ3 2026-$32.77M
VOR free cash flow was -$32.77M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$53.91M a year earlier. For the full fiscal 2025 it was -$143.65M, compared with -$99.89M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $321.53M | $93.31M | $94.31M | $64.55M | $47.53M | $31.62M |
| Selling, general and admin | $50.11M | $27.88M | $31.72M | $28.87M | $21.49M | $11.75M |
| Operating income | -$371.64M | -$121.19M | -$126.04M | -$93.42M | -$69.02M | -$43.37M |
| Net income | -$695.98M | -$116.91M | -$117.86M | -$92.09M | -$68.90M | -$43.34M |
| EPS, basic | -$70.50 | -$34.03 | -$35.00 | -$46.60 | -$42.00 | -$4611.40 |
| EPS, diluted | -$70.50 | -$34.03 | -$35.00 | -$46.60 | -$42.00 | -$4611.40 |
| Diluted shares | 9.9M | 3.4M | 3.4M | 2.0M | 1.7M | 10,682.9 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $396.49M | $81.95M | $31.36M | $57.71M | $119.80M | $48.54M |
| Short-term investments | $58.72M | $9.98M | $105.81M | $172.54M | $87.67M | $0 |
| Current assets | $458.11M | $96.51M | $140.80M | $236.95M | $214.40M | $49.11M |
| Total assets | $464.13M | $142.89M | $198.13M | $299.37M | $242.59M | $75.91M |
| Current liabilities | $25.17M | $18.61M | $15.57M | $13.12M | $10.15M | $10.21M |
| Total liabilities | $628.44M | $46.23M | $47.40M | $48.76M | $26.33M | $27.64M |
| Shareholders' equity | -$164.31M | $96.66M | $150.72M | $250.61M | $216.26M | -$59.06M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$142.71M | -$99.66M | -$100.29M | -$85.14M | -$69.14M | -$36.29M |
| Capital expenditures | $941.0K | $229.0K | $1.07M | $8.46M | $3.89M | $4.16M |
| Free cash flow | -$143.65M | -$99.89M | -$101.36M | -$93.61M | -$73.04M | -$40.45M |
| Investing cash flow | -$48.80M | $96.86M | $71.01M | -$94.09M | -$91.65M | -$4.16M |
| Financing cash flow | $503.81M | $53.39M | $2.94M | $117.14M | $232.91M | $82.53M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-based compensation | $18.91M | $9.85M | $13.36M | $10.70M | $4.32M | $1.34M |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $34.53M | $25.92M | $17.59M | $19.19M | $14.14M | $261.50M | $26.70M | $25.35M | $21.82M | $21.82M | $24.32M | $20.90M |
| Selling, general and admin | $23.91M | $21.93M | $17.57M | $16.77M | $13.96M | $12.79M | $6.59M | $5.96M | $6.70M | $7.21M | $8.00M | $7.23M |
| Operating income | -$58.44M | -$47.85M | -$35.16M | -$35.96M | -$28.11M | -$274.28M | -$33.29M | -$31.31M | -$28.51M | -$29.04M | -$32.33M | -$28.12M |
| Net income | -$86.73M | -$62.81M | -$219.58M | $1.72B | -$812.68M | -$1.57B | -$32.49M | -$30.71M | -$27.56M | -$27.84M | -$30.80M | -$26.26M |
| EPS, basic | -$1.45 | -$1.16 | -$5.11 | - | -$121.63 | -$251.24 | -$5.21 | -$8.78 | -$8.05 | -$8.20 | -$9.00 | -$7.60 |
| EPS, diluted | -$1.45 | -$1.16 | -$5.11 | - | -$121.63 | -$251.24 | -$5.21 | -$8.78 | -$8.05 | -$8.20 | -$9.00 | -$7.60 |
| Diluted shares | 59.7M | 54.3M | 43.0M | - | 6.7M | 6.3M | 6.2M | - | 3.4M | 3.4M | 3.4M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $78.98M | $107.86M | $169.87M | $396.49M | $160.46M | $190.57M | $50.05M | $81.95M | $52.80M | $76.08M | $44.96M | $31.36M |
| Short-term investments | $402.57M | $358.27M | $321.65M | $58.72M | $10.00M | $9.99M | $9.99M | $9.98M | $10.01M | $9.86M | $62.52M | $105.81M |
| Current assets | $490.52M | $475.11M | $500.78M | $458.11M | $172.49M | $204.93M | $64.85M | $96.51M | $67.30M | $90.26M | $111.82M | $140.80M |
| Total assets | $496.31M | $481.05M | $506.75M | $464.13M | $176.24M | $205.37M | $109.31M | $142.89M | $115.99M | $141.59M | $167.03M | $198.13M |
| Current liabilities | $36.34M | $24.81M | $16.08M | $25.17M | $18.84M | $58.77M | $16.73M | $18.61M | $14.35M | $13.80M | $13.21M | $15.57M |
| Total liabilities | $633.49M | $681.25M | $657.17M | $628.44M | $2.40B | $1.71B | $43.24M | $46.23M | $43.04M | $43.51M | $43.99M | $47.40M |
| Shareholders' equity | -$137.17M | -$200.20M | -$150.42M | -$164.31M | -$2.23B | -$1.51B | $66.07M | $96.66M | $72.95M | $98.08M | $123.03M | $150.72M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.75M | -$25.38M | -$38.25M | -$22.80M | -$53.66M | -$35.18M | -$31.07M | -$24.06M | -$23.29M | -$21.85M | -$30.46M | -$24.03M |
| Capital expenditures | $25.0K | $120.0K | $48.0K | $314.0K | $244.0K | $152.0K | $231.0K | $72.0K | $34.0K | $9.0K | $114.0K | $111.0K |
| Free cash flow | -$32.77M | -$25.50M | -$38.29M | -$23.11M | -$53.91M | -$35.34M | -$31.30M | -$24.14M | -$23.32M | -$21.86M | -$30.58M | -$24.14M |
| Investing cash flow | -$44.78M | -$36.53M | -$263.24M | -$48.97M | -$244.0K | $646.0K | -$230.0K | -$72.0K | -$34.0K | $52.99M | $43.97M | $10.34M |
| Financing cash flow | $48.65M | -$106.0K | $74.87M | $307.80M | $21.55M | $175.06M | -$606.0K | $53.29M | $41.0K | -$31.0K | $96.0K | $25.0K |
| Stock-based compensation | $9.94M | $9.40M | $8.87M | $7.11M | $8.03M | $1.84M | $1.93M | $1.71M | $2.26M | $2.79M | $3.08M | $1.89M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 13.50 | 19.15 | 31.15 | 18.20 | 9.16 | 3.49 | 3.88 | 5.19 | 4.69 | 6.54 | 8.46 | 9.04 |
Source: XBRL data Vor Biopharma Inc. files with the SEC, latest filing dated Oct 30, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Nov 13, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
VOR peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| VOR | - | - | $1.35B | - | $1.23B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
VOR FAQ
5 questionsIs VOR profitable?
Yes. Vor Biopharma Inc. earned $1.35B in net income for the twelve months ended Sep 30, 2026.How much cash and debt does VOR have?
Vor Biopharma Inc. reported $78.98M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is VOR free cash flow?
Vor Biopharma Inc. generated -$119.68M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$119.17M less capital expenditures.When did VOR last report financial results?
The latest statements here come from Vor Biopharma Inc.'s 10-Q filed on Oct 30, 2026, covering the period ended Sep 30, 2026.Where does this VOR financial data come from?
Quantisnow builds these statements from the structured XBRL data Vor Biopharma Inc. files with the SEC. It is provided for information only and is not investment advice.